Clinical Trial Update: Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and safety of LNP023 in C3 glomerulopathy patients, including transplanted and non-transplanted cohorts, has been completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Glomerulonephritis

Drugs mentioned

• LNP023 (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Glomerulonephritis | Phase 2 | Status: COMPLETED | Results posted: 2022-07-08